Evaluation of Dalfampridine Extended Release 5 and 10 mg in Multiple Sclerosis: A Randomized Controlled Trial

Background: Dalfampridine extended-release (ER) tablets, 10 mg twice daily, have been shown to improve walking in people with multiple sclerosis. We evaluated the safety and efficacy of dalfampridine-ER 5 mg compared with 10 mg. Methods: Patients were randomized to double-blind treatment with twice-...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Int J MS Care
Главные авторы: Yapundich, Robert, Applebee, Angela, Bethoux, Francois, Goldman, Myla D., Hutton, George J., Mass, Michele, Pardo, Gabriel, Klingler, Michael, Henney, Herbert R., Blight, Andrew R., Carrazana, Enrique J.
Формат: Artigo
Язык:Inglês
Опубликовано: The Consortium of Multiple Sclerosis Centers 2015
Предметы:
Articles
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4455866/
https://ncbi.nlm.nih.gov/pubmed/26052259
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7224/1537-2073.2014-040
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы